Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma

Table 7 Clinical studies of combined hepatocellular-cholangiocarcinoma

Source	n	Conclusion or findings
Yap et al[74]	11	Survival rate: 69.3% (3 yr)
Lee et al[75]	65	(1) The clinical characteristics of cHCC-CC are similar to those of HCC
		(2) Overall survival of cHCC-CC is similar to that of ICC
Yin et al[76]	113	(1) Findings similar to HCC: infection with hepatitis virus; presence of cirrhosis; elevated AFP levels
		(2) Findings similar to ICC: serum CA19-9 elevation; incomplete capsules; lymph node involvement
		(3) Survival rate: 41.4%(3 yr); 36.4% (5 yr)
		(4) Factors for poor prognosis: radical liver resection
Ariizumi et al[77]	44	(1) Survival rate: 24%
		(2) Median survival time: 15.4 mo
Yu et al[78]	14	(1) Clinical characteristics: hepatitis B virus infection: 13/14;
		elevated AFP levels: 11/14
		(2) Median survival time: 7.9 mo
		(3) Stem cell markers (IHC): c-Kit 71.4%; CD90: 85.7%; CD133: 92.9%; CK19: 78.6%
Park et al[79]	21	Factor for poor prognosis: serum AFP levels
Park et al[80]	43	(1) median survival time: 34 mo
		(2) Survival rate: 18.1% (5 yr)
		(3) Factors for poor prognosis: Portal vein thrombosis; distant metastasis
Zhan et al[81]	27	(1) CK-7: 86.4%; CK19: 90.9%
		(2) Survival rate: 49.4%
		(3) Factors for higher recurrence: lymph node metastasis

AFP: Alpha-fetoprotein.